CAR-T therapy yielded it's malignancy eradication efficacy via similar mechanism that lympho-system defensed against pathogen. Importantly, antigen presentation process involved MHC class recognition. I assumed that previous CD4/CD8 based CAR-T theory originated from this idea. But surely, you may try CAR-T involving other CD markers if feasible.